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Abstract
Background: Adverse drug events are a major cause of patient safety incidents. Current systems of
pharmacovigilance under-report adverse drug reactions (ADRs), especially in children, leading to delays in
their identiﬁcation. This is of particular concern, as children especially have an increased vulnerability toADRs.
Objectives: The objective was to seek consensus among healthcare professionals (HCPs) about barriers and
facilitators to the linkage of routinely collected health data for pediatric pharmacovigilance in Scotland.
Methods: ADelphi survey was conducted with a random sample of HCPs including nurses, pharmacists and
doctors,working inprimaryor secondary care, in Scotland.Participantswere identiﬁed fromsampling frames
of the target professionals such as an NHS workforce list for general practitioners and recruited by postal
invitation. A total of 819 HCPs were invited to take part. Those agreeing to participate were given the option
of completing the questionnaires online or as hard copy. Reminders were sent twice at a fortnightly interval.
Questions content included description of professional role as well as testing for the willingness to support the
proposed project and was informed by the Theoretical Domains Framework of Behavior Change (TDF) and
earlier qualitative work. Three Delphi rounds were administered, including a ﬁrst round for item generation.
Results: 121 of those invited agreed to take part (15%). The ﬁrst round of the Delphi study included 21 open
questions and generated over a 1000 individual statements from 61 participants that returned the
questionnaires (50.4%). These were rationalized to 149 items for the second round in which participants
rated their views on the importance (or not) of each item on a 9-point Likert scale (strongly disagree –
strongly agree). After the third round, there was consensus on items that focused on professional standards,
and practical requirements, overall there was support for data linkage and a multi-professional approach.
Conclusions: It would be acceptable to stakeholders to introduce a data linkage system for pharmaco-
vigilance as long as identiﬁed concerns are addressed. Concerns included adherence to current professional,
legal and ethical standards, as well resolving practical issues.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
It is generally acknowledged that, despite a
range of local or national incident reporting
schemes, the true rate of adverse drug reactions
(ADRs) is still signiﬁcantly under-reported,1,2
especially in children. This under-reporting is a
concern, as it delays the identiﬁcation of drug
related side eﬀects.
Patients at the extreme ends of the age spec-
trum are at greater risk of ADRs.3 Certain
enzyme functions or organs are not fully devel-
oped in young patients, especially children and
babies.4,5 Although in the UK, licensing require-
ments for medication include mandatory safety
data,6 this does not necessarily increase the safety
of drug treatment for children,7,8 as pediatric
medication was and is still not fully subjected to
the current licensing system in the UK.7 Many
of the drugs used in children do not have a license
for pediatric use, and are therefore ‘unlicensed’;
this unlicensed use is associated with an increased
likelihood of ADRs.9,10 Reported ﬁgures diﬀer,
but it is estimated that ﬁve out of eight severe
ADRs in pediatric inpatients are linked to oﬀ-
label use of drugs in children.11
A systematic review of papers published be-
tween 1986 and 2006 on the views of healthcare
professionals (HCPs) towards ADR reporting
found that under-reporting was related to lack
of knowledge of the reporting system (95%), lack
of time or similar reasons (77%), fear of ﬁling an
inappropriate report (72%), indiﬀerence and un-
certainty about causality (67%), and the percep-
tion that licensed drugs are safe (47%).1 Factors
associated positively with reporting were training
and medical specialty. For example, hospital
pharmacists were more likely to report an ADR
if they had received speciﬁc training.12
In the UK doctors, pharmacists, nurses and
patients can all report suspected ADRs by the
‘yellow card’ system.13 The yellow card system is a
spontaneous reporting system in the UK to collect
information from both HCPs and the general
public on suspected side eﬀects or ADRs to a
medicine. Despite a recommendation that all reac-
tions associated with medication used in children
must be reported, spontaneous analysis of data
for 1999–2003 shows only 7–13% of all reports
relate to children, suggesting that ADRs are
under-reported in children too.14
An alternative approach to spontaneous re-
porting of suspected ADRs, not dependent on
patient or HCP reporting, could be through the
linkage of routinely collected health care data in
primary and secondary healthcare settings.
CHIMES (Child Medical Records for Safer Med-
icines) was a project that investigated the accept-
ability and validity of linking datasets derived
from routinely collected NHS data. In Scotland,
such linkage is possible due to the use of a unique
patient identiﬁer, the community health index
(CHI) number, recorded for all National Health
Service (NHS) patient contacts. The proposed sets
for data linkage included the Scottish Morbidity
Records (SMR, datasets that collect key aspects
of health care related activity within NHS Scot-
land), as well as data held on attendance in
accident and emergency departments, data held
on death, the prescribing information available
from the Practice Team Information15 as well as
the Prescribing Information Service16 and GP
data held at the Primary Care Clinical Informatics
Unit (PCCIU).17 Linking datasets from primary
and secondary care would permit following pa-
tients in real time, providing denominators as
well as avoiding duplication of signals, i.e. report-
ing the same reaction twice. Routine data linkage
would permit creation of a continuous virtual
cohort to monitor for long-term outcomes, for
example after exposure to pharmacotherapy, and
enable a more efficient screening for side eﬀects
or ADRs due to an ever increasing data pool.18
Creating a cohort big enough can sometimes be
challenging in children if the group of patients is
below 1000, as can be the case for orphan drugs
or rare conditions.19 Combining existing datasets
could maximize the potential to identify safety is-
sues around pediatric medication.20
A recent review summarized the views and
opinions of HCPs to the secondary use of
routinely collected data, for a range of clinical
purposes, by either data sharing or linkage across
settings. The views were in general positive toward
data sharing. Identiﬁed barriers included costs,
governance issues and a perceived interference
with the prescriber and patient relationship.
Factors likely to facilitate data sharing were
involvement of relevant HCPs in designing the
system and perceived usefulness of the system,
particularly if HCPs recognized the potential for
improving quality of care and patient safety.12
Attempts to implement new initiatives for
identiﬁcation or reporting of ADRs are likely to
fail if potential barriers are not addressed.21
Whilst data linkage for pharmacovigilance would
not contravene current ethical, legal and practical
guidance,22–25 it is unclear whether frontline
268 Hopf et al. / Research in Social and Administrative Pharmacy 12 (2016) 267–280
HCPs would support the use of pediatric clinical
data for pharmacovigilance. Two qualitative
studies conducted with HCPs prior to the work re-
ported in this paper26,27 found that in general
views of the proposed data linkage were positive,
but there were also many potential concerns such
as conﬁdentiality and access to data.
For successful implementation of the pro-
posed data linkage system, it is essential that
frontline HCPs do not change their current
behavior and continue to collect and record
data. The Theoretical Domains Framework of
Behavior Change (TDF)27 is a theory-based
approach that allows areas of concern associated
with a particular behavior to be systematically
explored. It was identiﬁed as an appropriate
framework to use to identify the various concerns
associated with the introduction of the proposed
data linkage system for pharmacovigilance,
which would need to be addressed before full im-
plementation of the system.21,28–31 Delphi sur-
veys are an iterative consensus technique by
which issues are progressively reﬁned and
reduced in number to reﬂect the view of the ma-
jority.32 The aim of this study was to use a Del-
phi survey based on the TDF to seek consensus
among HCPs about the barriers and facilitators
to linking routinely collected data for pharmaco-
vigilance purposes.
Methods
The study design was a three round Delphi
survey, based on the TDF, distributed to a sample
of HCPs (doctors, nurses, pharmacists) in Scot-
land. The behaviors under investigation were
those that would ‘facilitate the proposed data
linkage’ and which were speciﬁed as three distinct
actions: (1) continuing to record data as usual, (2)
requesting consent and/or explaining opt-out, and
(3) reassuring the patients or their representatives,
i.e. explaining the purpose of the linkage to
patients/parents. The twelve TDF domains were:
(1) knowledge, (2) skills, (3) social and profes-
sional role and identity, (4) beliefs about capabil-
ities, (5) beliefs about consequences, (6)
motivation and goals, (7) memory, attention and
decision process, (8) environmental context and
resources, (9) social inﬂuences, (10) emotion, (11)
behavioral regulation, and (12) nature of behav-
iors.33 The study was approved by the North of
Scotland Research Ethics Service and NHS
Research and Development.
Participants
Doctors, nurses, and pharmacists currently
registered to practice in Scotland and whose scope
of practice included pediatrics were eligible for
participation in the study. HCPs who had partic-
ipated in preparatory related qualitative work
(interviews or focus groups26,27) were excluded.
Within a Delphi survey, experts are considered
to be “informed experts by reason of their day-to-
day involvement” with the question at hand.34 In
the case of this Delphi study, experts were consid-
ered to be frontline HCPs, i.e. HCPs currently
working as pharmacists, medics or nurses within
primary and secondary care, as this Delphi survey
aimed to explore potential (if any) barriers and
facilitators to the planned data linkage at grass-
roots level.
Identification, sampling & recruitment
A random sample of doctors (n ¼ 300), phar-
macists (n ¼ 300) and nurses (n ¼ 300) was drawn
from national sampling frames of the target pro-
fessionals (NHS Information Services Division
workforce list for general practitioners and prac-
tice nurses; community pharmacies from a list of
registered premises supplied by the Practitioner
Service Division (Scotland); pediatricians via the
Scottish Pediatric Society; pediatric nurses via
the clinical nurse managers of the main Scottish
children’s hospitals (Aberdeen, Dundee, Edin-
burgh, Glasgow)). They were invited to take
part as described below (see questionnaire
administration).
The Delphi Survey
The original authors of the Delphi technique
stated that “consensus is assumed to have been
achieved when a certain percentage of the votes
fall within a prescribed range”.32 The consensus
percentage for this Delphi study was set at
66.7% or more (40% or more for preference
items, i.e. questions that indicate a preference or
a choice) for Round 2 and for 90% or more for
Round 3.
Questionnaire development Round 1 – item
generation round
The development of the initial items for Delphi
Round 1 was informed by results from previously
conducted interviews29 and focus groups30
exploring a range of issues including potential
barriers. Twenty-one draft items were discussed
with a panel of experts (health psychologists,
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n ¼ 12) to check the comprehensibility of the
questions and to classify them into the 12 TDF
domains. Disagreements were resolved by discus-
sion. Fourteen items were clearly coded into a
theoretical domain. Four required discussion
before being assigned to a domain and two were
considered to relate to two or more domains. All
12 domains were represented (Table 1). Three
items concerning ownership of the unlinked and
linked data were considered project rather than
behavior related. The ﬁnal Round 1 questionnaire
consisted of a mixture of 21 open-ended questions
for item generation and multiple choice questions
for background and demographic data (all ques-
tionnaires are available on request).
Questionnaire development Round 2
Answers to the free-text questions in Round 1
were paraphrased into individual statements by the
lead author (YH). Item reduction followed the
method described by Prior et al36 using item de-
duplication, item reduction and removal of content
overlap. The ﬁnal list of items were presented in
Round 2 and participants were asked to rate their
agreementwith these statements ona9-point,Likert
scale (as shown in Fig. 1). Each statement was clas-
siﬁed according to the principles outlined in Table 2
with the majority of the statements further grouped
under an appropriate overarching statement.
Questionnaire development Round 3
Following the consensus criteria described
above, items that generated 66.7% or more
(40% or more for preference questions) of either
agreement or disagreement in Round 2 were taken
forward to Round 3. For each item, the scores
from Round 2 were presented to participants
before they were asked to rate their agreement
again on a scale from 1 (strongly disagree) to 9
(strongly agree) as shown in Fig. 1 (bottom).
Questionnaire administration
All potential participants received an invitation
letter, a study information sheet, and a consent
form. Two reminders were sent. Those agreeing to
take part were asked to indicate on the consent
form whether they would prefer a paper or an
online version of the questionnaire. For each
round participants were sent the appropriate sur-
vey either as a paper copy by post or as a web-link
by email. Regardless of response to earlier rounds
all participants were sent materials for each round.
A closing date for each round was provided.
Data management and analysis
Snap Surveys software was used to generate
the questionnaires (both paper based and online)
as well as to manage data entry. Data from
completed paper based questionnaires were
entered online using a speciﬁc link for each round.
All questionnaire data was then directly imported
into a Snap database, then exported to SPSS 1937
for statistical analysis, and to an Excel ﬁle (Excel
version 2007) to facilitate qualitative analysis of
free-text answers. Comparison of answers be-
tween diﬀerent healthcare professions was per-
formed using cross-tabulation. Wilcoxon
matched pair test was performed on all items to
test for statistically signiﬁcant shifts in opinion
for the Delphi-speciﬁc analysis after Round 3,
i.e. the analysis of responses from participants
who answered both Rounds 2 and 3.
Quality assurance
All questionnaires were piloted prior to distri-
bution in order to assess accessibility of the web-
link, understanding, and layout as well as
coverage of theoretical domains. Round 1 was
piloted amongst GPs (n ¼ 30) and community
pharmacists (n ¼ 30) local to the University to
test the suitability of the materials and to gauge
response rates. Round 2 was piloted in a focus
group consisting of 8 participants with a mixed
professional background (experience with TDF
n ¼ 3, GPs n ¼ 2, Pharmacist n ¼ 1, Nurse
n ¼ 1, Psychology n ¼ 1). Three members of the
previous focus group testing Round 2 materials
agreed to pilot the Round 3 materials as well.
This ensured consistency with the Delphi process
(repeated exposure).
Inclusion of items for Round 2 was discussed
with members of the project team (JF, CB) who
also contributed to the item reduction process
between Rounds 1 and 2. The categorization of
the items in Round 3 into theoretical domains was
performed independently by the researcher (YH),
one supervisor (JF) and a health psychologist
(ED) with experience in the use of the TDF.
Disagreement was resolved by discussion.
Results
The Delphi survey was conducted in three
Rounds from August 2011 to February 2012. The
Round 1 participants (n ¼ 61) provided 1006 indi-
vidual answers to free-text questions. These were
paraphrased into 1148 individual statements by
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Table 1
Initial Item Generation for Round 1 (only items related to the TDF are listed)
Domain Item
Knowledge
(Describe my experience and awareness of the issue/
procedure/technique in question)
 Do you have any experience with data linkage?
 Have you heard about these datasets before?
Skills
(My own competence and ability to perform a task or
behavior)
 Have you used these datasets before?
Social/Professional role and identity
(Description of my professional role)
 Are your professional standards in conﬂict with the
proposed data linkage?
Belief about capabilities
(Belief about whether I am able to perform the target
behavior)
 How conﬁdent would you feel to facilitate the pro-
posed data linkage?
Belief about consequences
(What will follow the introduction of the proposed data
linkage from my point of view)
 What would be the beneﬁts/drawbacks of the pro-
posed data linkage?
 How long will it take for these (beneﬁts and draw-
backs) to show?
Reinforcement*
(What could increase my intention/willingness to
facilitate the proposed data linkage)
 Would it make you more likely to facilitate the pro-
posed data linkage if you were to receive a ﬁnancial
incentive/results or feedback?
Intention#
(Testing my willingness to perform a speciﬁc task/
procedure/technique)
 If the proposed data linkage infrastructure were to be
available, would you facilitate it?
Goal#
(Testing potential interference of the planned
intervention to my own objectives)
 Would facilitating the proposed data linkage interfere
with anything you would like to achieve in your pro-
fessional practice?
Memory, attention and decision process
(Exploring the thought processes behindmydecisions and
behavior, whether it is something that requires me to
focus on performing the behavior in question, and if so,
would I forget to do so if I am distracted or busy)
 Would facilitating the proposed data linkage require
your particular attention during a consultation with a
patient or in your day-to-day work?
Environmental context and resources
(Exploring any barriers to the proposed data linkage due
to given circumstances and availability of resources)
 Are the necessary resources available for the proposed
data linkage?
 Which are they?
Social influences
(Inﬂuences on my behavior by patients, peers, ethical
norms)
 To what extent would other people’s views inﬂuence
your own opinion about the proposed data linkage?
Emotion
(Consideration of feelings that might be involved with
the task in question)
 Would you have any worries or concerns about the
proposed data linkage?
 What are they?
Behavioral regulation
(Examination of steps required to enable the proposed
task)
 Who would need to do what in preparation for the
proposed data linkage?
Nature of behaviors
(Description of the behavior required for the proposed
task and investigating whether a behavioral change is
required to accommodate the proposed task/
intervention)
 Do you have any experience with data linkage?
 How diﬀerent is the proposed data linkage from what
you have experienced before?
 Can you explain the diﬀerences?
Column one denotes the domain (NB: in a more recent version of the TDF ‘Reinforcement’* is part of the domain
‘Belief about Consequences’, and ‘Intention’# and ‘Goal’# are part of the domain; ‘Motivation & Goals’.35
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the lead author (YH); item de-duplication removed
383 statements, item reduction removed a further
108 statements, and removal of content overlap a
further 488 statements, leaving 169 statements.Dur-
ing thepilot of theRound2questionnaire, all partic-
ipants reported that a block of questions (n ¼ 20)
was too complicated and did not add to the value
of the questionnaire. This block of questions was
subsequently removed, leaving 149 items for inclu-
sion in Round 2. A total of 46 items qualiﬁed for in-
clusion in Round 3.
Response rates
Of 819 valid invitations sent, 121 participants
agreed to take part (15%) and 189 declined (23%).
Response rates varied throughout the rounds, with
50.4% for Round 1 (n ¼ 61), 35.7% for Round 2
(n ¼ 46), and 37.9% for Round 3 (n ¼ 50). An
overview of the questionnaires sent and returned
through the rounds is presented in Table 3.
Demographics
An overview of key demographic data for
each round is presented in Table 4. A total of 27
participants provided data for both Round 2 and
3 (‘Delphi’ Group). The majority of these partic-
ipants were between the age of 45–65 (77.8%,
n ¼ 21) and female (80.8%, n ¼ 21; one partici-
pant chose not to answer). Medical doctors
were the biggest respondent group with 40.7%
(n ¼ 11), followed by nurses (37%, n ¼ 10). Par-
ticipants were employed in seven diﬀerent health
boards, with most from Greater Glasgow and
Fig. 1. Example for the layout of questions in Round 2 (top) and 3 (bottom).
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Clyde (29.6%, n ¼ 8), closely followed by Gram-
pian (25.9%, n ¼ 7).
Quantitative results Round 1
Only a small proportion (4.9%, n ¼ 3) of par-
ticipants reported that the proposed data linkage
would be in conﬂict with their professional stan-
dards. The majority of medical doctors (70.8%,
n ¼ 17) considered the proposed linkage to be in
line with their professional guidance compared
with 40% (n ¼ 6) of pharmacists and 38.1%
(n ¼ 8) of nurses. None of the participants who
felt that their professional standards were in con-
ﬂict with the proposed data linkage provided
further explanation when prompted.
The majority of participants (67.2%, n¼ 41) re-
ported no prior experience with linked datasets. A
third of participants were either ‘conﬁdent’
(32.8%, n ¼ 20) or ‘very conﬁdent’ (4.9%, n ¼ 3)
that they would be comfortable in facilitating the
proposed data linkage. However, participants
would facilitate the linkage conditionally with
42.4% (n ¼ 25) for the whole cohort including
22% (n ¼ 13) of unconditional support.
The majority of respondents indicated that a
ﬁnancial incentive would make no diﬀerence to
their willingness to facilitate the linkage (62.3%,
n ¼ 38). Pharmacists (33.3%, n ¼ 5) were more in-
clined to want a ﬁnancial incentive compared to
4.8% (n ¼ 1) of nurses. The majority (63.3%,
n ¼ 38) also reported being in favor of receiving
general feedback of results in return for facili-
tating the linkage.
Just over one-third (38.3%, n ¼ 23) reported
that resources, such as access to computers, would
not be available for the linkage. A summary of all
answers are shown in Fig. 2.
A third of the participants (n ¼ 19) provided
free-text comments indicating that further infor-
mation on the datasets used and the proposed
data linkage would be required for participants
to reach a ﬁrm conclusion:
“This is an interesting project, but it would be
useful to know more details of what datasets will
be linked and how.”(GP, C20)
Additional information on this and other
points arising from free-text entries were subse-
quently taken into account in the production of
the subsequent two Delphi rounds.
Results Round 2
A total of 46 items (31%) matched the pre-
deﬁned inclusion percentage of 66.7% after
Round 2.
Consensus after Round 3
The 13 items for which consensus were greater
than 90% in the Delphi group were included in
the ﬁnal analysis (Table 5).
Table 2
Categories for statements after paraphrasing individual
answers from Round 1 (ﬁrst column states the category;
the second column gives examples of usage)
Result (no further action) These statements were
straightforward results
(i.e. not requiring further
interpretation), an
example are the answers
provided to the question 2
(“Who do you think these
datasets belong to?”)
Round 2 These statements were
moved onto Round 2
directly, e.g.
“It is necessary that patients
have thechance toopt-out”
(answer to question 24)
Round 2 with adaptation For statements that dealt
with a similar concept,
e.g. the items
‘The NMC would have to
comment on the policies
and procedures.’
‘GP bodies would have to
consent on the data
linkage.’
Were combined to
“The respective professional
bodies would have to
approve the linkage.”
Instructions/Front page As several answers to
diﬀerent questions were
“I would need more
information before I can
make a decision.” more
detailed information on
e.g. the planned linkage
was provided in the
instruction for Round 2.
Excluded Statements were excluded if
referring to irrelevant
answers such as “I do not
have time in my daily
practice to consider
further paperwork.” [NB:
Facilitating the linkage is
not linked to further
paperwork.]
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Coverage of Theoretical Domains Framework
Using the TDF of Behavior Change to struc-
ture Round 1, the domain ‘nature of behaviors’
was omitted after Round 2. A further two
domains, ‘emotion’ and ‘memory, attention and
decision process’ were omitted after Round 3.
For Round 3, consensus was achieved for
allocation of 18 items to one of the prior agreed
theoretical domains. For an additional 20 items
(43%) two of the three assessors agreed and the
majority decisionwas accepted. Consensus for eight
items was reached by discussion and 10 could not
clearly be attributed as they described conditions
related to the behavior rather than factors that
might inﬂuence the behavior itself (the latter being a
requirement for TDF classiﬁcation33).
Nine of the 12 domains were populated. Two
items were allocated to two domains; “The appro-
priate IT resources would need to be in place before
I can facilitate the linkage” and “The government
would need to provide funding for the information
to be collated and the website to be designed and
built” could either be part of ‘behavioral regula-
tion’ and ‘environmental context and resources’.
Items allocated to ﬁve theoretical domains,
namely “Social Inﬂuences”, “Social Role & Iden-
tity”, “Knowledge”, “Behavioral Regulation” and
“Environmental Context & Resources”, were
included in 11 of the 13 items in the O90%
agreement group; the two remaining items were
classiﬁed as ‘conditionals’ (as shown in Table 5).
Discussion
Main findings
Participants were generally willing to facilitate
data linkage as long as adherence to their respec-
tive professional standards was maintained and
they were given reassurance about the practical
aspects of implementation.
Table 4
Tabulated demographics for respondents of the ﬁnal two rounds
Round 1 Round 2 Round 3 Delphi Groupb
Number of respondents 61 46 50 27
Age (45–65 years of age)a 72.1% (44/61) 79.4% (27/34) 70.8% (34/48) 77.8% (21/27)
Gender (female)a 71.9% (41/57) 87.9% (29/33) 78.7% (37/47) 80.8% (21/26)
Professional backgrounda
Medical doctors 40.0% (24/60) 32.4% (11/34) 39.6% (19/48) 40.7% (11/27)
Nurses 35.0% (21/60) 47.1% (16/34) 39.6% (19/48) 37.0% (10/27)
Pharmacists 25.0% (15/60) 20.6% (7/34) 20.8% (10/48) 22.2% (6/27)
Main settingc
Primary care 62.0% (n ¼ 38) 56.0% (n ¼ 19) 50.0% (n ¼ 25) 52.0% (n ¼ 14)
Secondary care 41.0% (n ¼ 25) 47.0% (n ¼ 16) 48.0% (n ¼ 24) 52.0% (n ¼ 14)
Health boards responding 11 10 10 7
Median No of children [IQR] 3 [1–3] 3.5 [2–4] 3 [1–3] 3 [1–3]
a Demographic data not available for full cohort, numbers in brackets show respondents over the available
denominator.
b This column describes the participants who answered Round 2 and Round 3.
c Participants could work in more than one setting, not all participants provided an answer.
Table 3
Numbers of questionnaires sent out and received for each round
Number of questionnaire sent Number of questionnaires received Response rate
(%)
Postal Online Total Postal Online Total
Round 1 35 86 121 18þ1a 43þ3b 61þ1aþ3b 50.4
Round 2 42 87 129 17þ3c 29 46þ3c 35.7
Round 3 42 90 132 19 31 50 37.9
a Spoilt.
b Duplicates.
c Received after data closing.
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Strengths and limitations
Due to the large number of questions asked in
Round 1 and in order to cover all relevant TDF
domains a systematic data reduction exercise was
applied to keep the length of the following rounds
manageable.36 Emphasis was on retaining as
much of the original wording and context as
possible and care was taken to include minority
and majority statements in Round 2.38 However
as in all such Delphi exercises item reduction
may result in the loss of some subtleties and nu-
ances contained in Round 1.
Not all participants who contributed toRound 1
completed subsequent rounds and, based on sub-
mitted study ID numbers of respondents, partici-
pants who were not involved in Round 1
contributed to Rounds 2 and 3. However this was
unlikely to compromise the study as Round 1 was
designed to create a list of statements that could be
rated in the consecutive rounds and the Delphi
analysis (i.e. the repeated rating of the same
statements) only included participants who contrib-
uted to both rounds 2 and 3. PreviousDelphi studies
have described diﬀerent participant samples for
consecutive rounds34,39 or have replaced the initial
qualitative round, with a literature review in order
to generate statements for the quantitative rounds.40
Although the questionnaire instructions
included information about the potential datasets
that could be used in the proposed linkage,
comments provided in the questionnaires indi-
cated that participants did not understand some
of the terms and abbreviations used-indicating
that more information besides the explanation of
the abbreviation would have been helpful.
Although the current lack of awareness about
available clinical and administrative datasets that
are routinely collected limits the interpretation of
some of the expressed views it highlights the need
for eﬀective communication of the proposed and
future linkages and training needs of HCPs.
This Delphi survey was initially planned as a
large scale survey, with a target sample of 300
participants. Contributions were received from 61
participants only in Round 1. Poor response rates
have been reported before with Delphi surveys,
attributed to the immense eﬀort that is required
by participants such as repetitive questioning, not
seeing the relevance or justiﬁcation for ques-
tions.34,41 However, the sample in this study
Fig. 2. Results of quantitative questions in Round 1.
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included participants from all relevant profes-
sional backgrounds and the majority of Scottish
Health Boards and participant numbers were
well within the range of previously reported Del-
phi studies.34,40
Planned cross-tabulation for associations of
responses in professional grouping could not be
performed due to small numbers.
Views of healthcare professionals towards
facilitating data linkage
Despite the majority of HCPs reporting in this
study that they had no experience with data
linkage, a third would still facilitate the proposed
data linkage. Low conﬁdence seemed to be
associated with a lack of understanding of the
proposed data linkage details of what would be
expected of the participants, i.e. patients. Previous
studies have shown that unawareness of data
sharing procedures42 and lack of knowledge as
to how routine data would be used43 could
become a barrier to the implementation of health
information exchange. Participants expressing
conﬁdence in facilitating the proposed data link-
age additionally requested further training and
information.
Previous investigations of potential data link-
age systems have identiﬁed ﬁnances, concerns
over data governance, and technical problems as
barriers to an eﬀective linked pharmacovigilance
system.12 However, none have taken a behavioral
approach. Participating in an eﬀective and robust
data linkage system would require HCPs to do
things diﬀerently, i.e. to change their behavior.
Hence a recently developed theoretical model de-
signed to identify barriers to changing HCP
behavior was used here. The advantage of
applying this model is that it provides an evidence
base by identifying theoretical determinants of
behavior that could then be targeted by interven-
tions to support practice change.44
Coverage of all theoretical domains occurred in
Round 1, indicating that a comprehensive range of
potential issues had been identiﬁed in the qualita-
tive studies conducted prior to the Delphi. Over
three rounds, there was a reduction in the number
of domains resulting in identiﬁcation of a sub-set
Table 5
Consensus items by percentage agreement (participants answering 7, 8, or 9)
Item No Item [TDF domain] Agreement (%)
9a When working as part of a team it is important to consider the views of all team
members. [Social inﬂuences]
100
2a Facilitating the linkage is not in conﬂict with my professional standards if the data is
anonymized. [Social role & identity]
96.3
103a The agencies that currently hold the diﬀerent datasets need to agree to the sharing of the
data. [‘Conditionals’b]
96.3
105 A good understanding amongst health professionals of the purpose and the beneﬁts of
the linkage is required. [Knowledge]
96.3
107 The appropriate IT resources would need to be in place before I can facilitate the
linkage. [Behavioral regulation]
96.3
121 Adverse events in secondary care need to be recorded electronically. [Environmental
context & resources]
96.3
128a Employers would have to support the facilitation of the linkage. [Behavioral regulation] 96.3
106 Ethical approval for the data linkage is required. [Behavioral regulation] 92.6
109 Prescribers would have to accurately record the indication for the treatment for the data
linkage to be successful. [Behavioral regulation]
92.6
3a My professional guidelines do not conﬂict with my facilitation the linkage. [Social role &
identity]
92.5
104a A general awareness of the importance of accurate data handling would be required.
[‘Conditionals’]
92.2
129a A multi-professional approach would be required for initiating necessary changes.
[Behavioral regulation]
92.2
4a Facilitating the linkage is not in conﬂict with my professional standards as long as
conﬁdentiality is ensured. [Social role & identity]
92.2
a marks items with a signiﬁcant shift between Rounds 2 and 3 (Wilcoxon matched pair test).
b ‘Conditionals’ do not represent a current domain of the TDF but are included here for completion.
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of domains most relevant to the implementation of
the new system namely ‘behavioral regulation’,
‘social/professional role & identity’, ‘belief about
consequences’, ‘environmental context & re-
sources’ and ‘Belief of consequences (reinforce-
ment)’. This reduction of relevant domains allowed
the identiﬁcation of ways in which identiﬁed
barriers could be addressed, as discussed in more
detail below.
The domain associated with the largest single
number of items (n ¼ 5) was ‘Behavioral Regula-
tion’, which identiﬁed that ethical approval (item
106), support from employers (item 128) and the
accurate recording of indication for treatment
(item 109) would be needed before HCPs would
give their support. Participants agreed that a
multi-professional approach (item 129) would be
necessary to implement such a system and
encourage the reporting of adverse reactions not
only by medical doctors but all HCPs, including
specialist nurses and pharmacists authorized to
prescribe and monitor.45
Consensus items within the domain ‘social/
professional role and identity discussed whether
the proposed data linkage was consistent with
professional responsibility or professional guid-
ance. The results in the present study demon-
strated that participants felt that their own
professional standards of practice would not be
in conﬂict with the proposed data linkage.
Although several items relating to the domain
‘beliefs about consequences’ (e.g. ‘facilitating the
linkage would result in safer prescribing’ or
‘facilitating the linkage would result in identifying
risky prescribing patterns’) fulﬁlled the pre-
deﬁned criteria for inclusion in Round 3, on
further ranking the level of participant agreement
decreased. This could have been due to the
growing awareness that the proposed linkage
would not result in a patient-level identiﬁable
database for prescribers, i.e. a database where
individual patients could be identiﬁed, but rather
a national resource for signal generation to
identify potential ADRs.
Statements about resources and the environ-
mental context were apparent through all rounds
and identiﬁed perceived barriers due to the given
circumstances within the NHS and the availability
of resources conditions as well as lack of local IT
resource and access. Requests for required re-
sources centered on IT and the need to record and
check data relating to their own practice and more
speciﬁcally to the identiﬁcation and reporting of
ADRs electronically despite the availability of the
current ‘Yellow Card’ system in paper and elec-
tronic format.13 The quality of the potentially
available data for linking in terms of its complete-
ness and comparability remained an issue
although previous research has demonstrated
that the data quality of linked data bases can be
increased by employing strict internal quality con-
trols and validation.46,47 These consistent views of
HCPs involved in direct patient contact points to
an important need to involve them more directly
in system design and to encourage their active
participation by demonstrating the advantages
of using linked aggregated national and large scale
regional linked data to address important quality
and public health concerns such as prescribing
and drug safety.
The requirements identiﬁed by the participants
in addition to the work conducted prior to the
Delphi study26,27 showed that HCPs would need
reassurance before giving full support for the pro-
posed use of linked health data. The “conditional”
statements were about the necessity for accurate
data recording by frontline HCPs and official pro-
cedures for data sharing. However, these state-
ments did not ﬁt the TDF as they did not relate
to the participants’ willingness (or intention) to
facilitate the proposed data linkage but rather
the need for the results of linkage studies to pro-
vide information directly relevant to their own
clinical practice. For example, clinically useful re-
sults from the analysis of the linked data could
create a stimulus for HCPs to facilitate the pro-
posed linkage. Participants in favor of receiving
this kind of incentive thought that data linkage
should provide useful audit tools thereby encour-
aging their participation. However, participants
who answered that they were not more likely to
facilitate data linkage after receiving such feed-
back indicated their general support of the linkage
regardless of any incentives.
Although ﬁnancial incentives were not perceived
as a facilitator per se, pharmacists in particular com-
mented that ﬁnancial incentives would increase sup-
port whereas this was only mentioned by a very
small percentage of nurses. This diﬀerence could
reﬂect the fact that the majority of pharmacists in
the sample were working in community pharmacy
settings and who were well used to remuneration
for services.
Most items regarding data ownership were
dismissed as they did not reach the pre-deﬁned
agreement rate, with the exception of the following
statement that ‘the agencies that currently hold the
diﬀerent datasets need to agree to the sharing of the
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data’, thus indicating a belief that datasets be-
longed to the data collector and that consent to the
use and sharing of the data by these designated data
guardians was important. However, the fact that
data ownership was not identiﬁed as a major
problem might be due to the reported lack of
awareness of current data owners and guardians.
Identification of essential system components for
data linkage
HCPs commented that the proposed data
linkage and system design would have to take
account of multi-disciplinary working in the
clinical care of children and would have to address
legal, ethical, and practical issues including recog-
nition by their line managers of the required time
commitment to data veriﬁcation and data quality.
HCPs would support the data linkage if it
complied with their professional standards
including working principles (for pharmacists),
duties (for medical doctors), or codes (for nurses).
Each professional body oﬀers additional guidance
on those points, specifying further details. The
guidelines of the General Pharmaceutical Council
(GPhC) for pharmacists, for example, states that
pharmacists should comply with “relevant legisla-
tive requirements”,48 providing as examples the
Data Protection Act and common law principles.
Compliance is also expected with non-statutory
guidelines that might apply to clinical practice,
such as NHS policies or Caldicott principles. Cal-
dicott stands for a set of principles and processes
which provide a framework of quality standards
for the management of conﬁdentiality and access
to patient identiﬁable information under the lead-
ership of so-called Caldicott Guardians (named
responsible person). The extended guidelines con-
cerning conﬁdentiality as published by the Gen-
eral Medical Council (GMC) also state that
doctors are expected to follow local policies and
guidelines as well as comply with relevant legisla-
tion.49 Complying with professional standards
that could inadvertently result in identiﬁcation
of individual patients would require some form
of patient involvement prior to data linkage.
This does not imply the need for an opt-in system
but could allow a readily identiﬁable opt-out sys-
tem as long as patients, in this case children and
their parents or guardians, were informed about
the purpose of the linkage, how the data would
be linked and stored and what the linked data
would be used for. Relevant parts of the Data
Protection Act and the Common Law Duty of
Conﬁdentiality for data processing and anonym-
ization also need to be considered in system
designs.
HCPs identiﬁed evidence of ethical approval
for the linkage as an absolute requirement. How-
ever, details of the ideal process still need discus-
sion. Who could or would provide ethical
approval for the data linkage, and what would
the scope be, for example for single studies only or
as umbrella approval for all signal generation
studies? For the UK, a proportionate review for
the use of medical data has been proposed.50
Employees who indicated their support also
acknowledged that their participation would be
dependent on their employer’s opinion suggesting
the need to convince/win over not only the
frontline HCPs responsible for data collection
but also higher level stakeholders, including
managers and administrators within the NHS/
healthcare system about the potential beneﬁt of
data linkage for pediatric pharmacovigilance. The
support requested was not speciﬁed other than the
need for training and provision of necessary IT
resources. Although the majority of IT resources
would be needed for the construction of the linked
datasets, results of the Delphi suggested that
participants wanted to be able to record suspected
ADRs and indications for medication directly on
the electronic data management system relevant
to their practice. Although this is currently done
in paperless primary care practices, albeit to a
varying degree, ADRs are not routinely recorded
in hospitals in an electronic and hence accessible
and linkable format.
The lack of knowledge about existing clinical
and administrative datasets available for linkage
within NHS Scotland could explain in part the
perceived need for data sharing agreements from
current data owners. The shift between rounds
might well be a result of participants being swayed
towards selecting a higher score. Another possible
reason for this change could be that the time
between rounds which allowed participants to
reﬂect and possibly research the issue at hand.
Conclusion
In general, the health care practitioners sur-
veyed here indicated intention to facilitate the
proposed data linkage, albeit with some reserva-
tions. Some system requirements were identiﬁed
that might be necessary to secure more active
support from frontline HCPs for the proposed
data linkage. Professional standardswere identiﬁed
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as important, together with a need to adhere to
multiple legal and ethical considerations. Three
levels of requirements for systemdesignwould have
to be addressed namely adherence to current legal
and ethical standards, support from higher level
stakeholders in theNHS and associated employers,
and the practical requisites for the data linkage
including server space and locally accessible IT
resources to record data electronically.
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